Introduction
Mesenchymal stem cells (MSCs) have recently been investigated as a possible powerful tool for aiding bone repair in peculiar indications [1] [2] [3] [4] [5] . Bone marrow-derived MSCs (BM-MSCs) have been shown to be useful in both pre-clinical [3, 6, 7] and clinical [1, 7, 8] studies, with and without cell culturing and with or without a matrix. Major indications include large segments of bone lost owing to trauma (requiring reconstruction), tumors and skeletal deformities (requiring resection), avascular necrosis, and non-unions or delayed unions [1, 2, 4, 9, 10] . Specifically, delayed unions and nonunions are still frequent and major complications of the treatment of fractures, and cell therapy may represent a valid and better alternative to the use of bone grafting procedures or, simply, osteoconductive substitutes [2, 9] . Several researchers have described the similarity between BM-MSCs and adipose-derived stem cells (ASCs), as well as the potential use of ASCs in bone regeneration [4, 5, 11, 12] .
Subcutaneous adipose tissue is an attractive reservoir of progenitor cells because it is easily accessible, abundant and selfreplenishing. The stromal vascular fraction (SVF) of adipose tissue consists of a heterogeneous mixture of cells, including endothelial cells, smooth muscle cells, pericytes, leukocytes, mast cells, and pre-adipocytes [11, [13] [14] [15] . In addition to these cells, the SVF contains an abundant population of multipotent ASCs that have the capacity to differentiate into cells of mesodermal origin "in vitro", e.g. adipocytes, chondrocytes, osteoblasts, and cardiomyocytes [11, [13] [14] [15] [16] [17] [18] [19] .
In the present paper, we describe a practical protocol for harvesting and isolating autologous ASCs, ready to be used for intraoperative cell therapy for bone repair.
Materials and methods
In the immediate preoperative period, a single dose of 1.5 g of ampicillin sodium + sulbactam sodium was given intravenously. The procedures were performed under sedo-analgesia using the tumescent technique (Fig. 1A) , infiltrating the subcutaneous tissue of the abdominal region with Klein solution [20] : 0.9% NaCl 1000 mL, lidocaine 1000 mg (0.1%), 8.4% sodium bicarbonate 15 mL, and adrenalin 0.5 mg (concentration 1:2000000). The volume of injected fluid was proportional to the estimated volume to be extracted by liposuction (usually 100 cm 3 Step 1: after conventional infiltration (A) and liposuction (B), the harvested fat is ready (C) to be mixed with a collagenase digestion solution; further steps are incubation (D) for 30 min. At 37
• C, washing (E) with saline solution to remove collagenase, centrifuge (1600 RPM × 6 min.) (F) and further washing (G, H) to obtain the ASCs pellet (I).
abdominal liposuction was performed using 2-mm blunt cannulas (Fig. 1B) . The devices used (Lipokit-Celltibator, Medi-Khan Inc., USA) were designed for tumescent injection, aspiration, harvesting, filtering, and processing of autologous fat tissue in a closed circuit, thus avoiding any risks of contamination. However, the same procedure might just as easily be performed with cannulas connected to Luer-Lock 50 cm 3 syringes. The lipoaspirate was then processed according to the following procedure: about 50 mL of highly concentrated adipose tissue (Fig. 1C ) was mixed rapidly with 1 g of collagenase (Collagenase NB 6 GMP Grade #17458, Serva GmbH, Heidelberg, Germany), previously diluted with 50 mL of sterile phosphate-buffered saline (PBS). The resultant cellular suspension (lipoaspirate + collagenase solution) was then incubated for 30 min (Fig. 1D) at 37 • C. Subsequently, only 10 mL of solution (containing the SVF pellet) remained; this solution was then washed three times (Fig. 1E ) in 45 mL saline solution. After each wash, the syringes containing the SVF were positioned inside the centrifuge at 200 RCF × 4 min (Fig. 1F) . At the end of the procedure, a 5-cm 3 saline sample, containing the ASC pellet, was ready for its application in regenerative medicine ( Fig. 1G-I ). The whole procedure lasted about 120 min.
Processed lipoaspirates from three healthy patients were studied. Surface markers of the isolated ASCs were analyzed by flow cytometry according to the criteria for defining multipotent mesenchymal stromal cells, as defined by the International Society for Cellular Therapy [21] . Following our previously described protocol [22] , the cells were incubated for 20 min and stained with antibodies specific for human ASC markers: CD10, CD13, CD31, CD33, CD34, CD39, CD44, CD45, CD59, CD73, CD90, CD102, CD106, CD146, HLADR, and HLAABC (Becton, Dickinson and Co., NJ, USA). The cells were analyzed using an eight-color flow cytometer (FACSCanto II; Becton, Dickinson and Co., NJ, USA). The dye 7-amino-actinomycin D (7-AAD) was added to assess the viability of the cells. At least 20,000 events were collected.
Results
A mean of 2.5 × 10 6 cells was isolated per procedure: 35% (875,000) of these were CD34+/CD45− cells ( Fig. 2A) , which expressed a subset of both positive (CD10, CD13, CD44, CD59, CD73, CD90, HLAABC) and negative (CD33, CD39, CD102, CD106, CD146, HLADR) cell-associated surface antigens, characterizing them as ASCs; 60% (Fig. 2B) were CD34+CD45−CD31− cells (20% total cells; 525,000 cells), and 40% were CD34+CD45−CD31+ cells (14% total cells; 350,000 cells). The overall viability of these cells was equal to 93% (Fig. 2C ).
Discussion
The harvesting of BM-MSCs has practical constraints. These include pain at the harvest site, and harvest of only a small volume of bone marrow (and therefore a small number of MSCs), meaning that ex-vivo expansion of the cells is probably necessary to obtain clinically significant cell numbers. Moreover, an inverse correlation between age and differentiation potential of BM-MSCs has been reported, with use of these cells being a challenge in elderly patients [1, 16] . By our protocol, it is possible to obtain, within about 2 hours, a mean of 8.75 × 10 5 highly purified, vital ASCs, ready to be used in the same operative session.
Our procedure differs from protocols previously described in literature (e.g. 14), since these add Minimum Essential Medium containing 20% heat-inactivated fetal bovine serum to the tissue sample. This is not necessary with our protocol. There are no studies establishing fetal bovine serum security as regard its clinical use. Our isolation procedure is performed step by step by a closed circuit system, in the same operating theatre of the liposuction procedure, thus minimizing the risks of contamination. Neither serum nor animal-derived reagents are used, making this strategy easier, cheaper, and safer, minimizing the possibility of immune reactions.
The harvesting of ASCs offers several advantages over BM-MSCs: abundant donor tissue, plentiful number of cells, patient compliance, ease of procedure, minimal postoperative complication rate, and no need for cell culture or amplification. The number of BM-MSCs contained in 1 mL of aspirated bone marrow ranges from 108 to 612 ± 134 [7, 23] . Since the number of cells rapidly decreases after the first aspiration, the BM-MSCs obtained by aspiration of 10-40 mL of bone marrow from the iliac crest ranges from 1.5 × 10 3 /mL to 2.5 × 10 3 /mL, also taking into account concentration procedures [7, 23] .
All the major described method of ASCs harvesting contemplate lidocaine and adrenaline injection, and this do not hamper cell viability [24] .
Complication (mainly: hematoma, seroma, infection) rate of liposuction is low (0.1%) [25] .
Based on our protocol, the number of stem cells derivable from adipose tissue is 1430-fold more than the number derivable from bone marrow. Bearing in mind that it is not unusual to lipoaspirate 1 L (and much more) of adipose tissue, the number of obtainable ASCs may be further multiplied by a factor of 20 (about 1.75 × 10 7 ASCs per procedure).
A similar number of BM-MSCs could only be obtained, of course, by extensive cell culture procedures [23] . However, extensive passaging results in loss of function in addition to mutations and potential carcinogenic effects [5] ; moreover, cell amplification procedures must follow strict legislative protocols, rely on certified Good Manufacturing Practice (GMP) laboratories, require two operative procedures, and are very expensive.
The benefits of the "one-step" technique for patients are that it requires only a single session of surgery, in which ASCs are both harvested and applied at the same time (in the operating theater) and it does not require a lengthy cell expansion time or multiple visits to the clinic. Limiting the ex-vivo manipulation of these cells provides a more favorable technique for future clinical applications, thus highlighting the intrinsic ability of ASCs to adapt to their environment in vivo without the need for exogenous growth factors and substrates pre-transplantation [26] .
Some authors demonstrated ASCs cells to have a similar growth kinetics, cell senescence, and osteogenic differentiation capacity in vitro as BM-MSCs [11] , though others have shown BM-MSCs to have superior growth kinetics and differentiation capacities [18, 27] . Mutations and carcinogenic effects have never been described; however, lack of description does not mean lack of effect, and this eventuality cannot be excluded.
Several pre-clinical studies have demonstrated the capability of such cells to undergo and promote differentiation into osteoblastic cells in animal models [28, 29] .
Anyhow, there is still controversy over the osteogenic power of ASCs respect to MSCs: some studies have shown the increased osteogenic potential of marrow-derived MSCs, whereas others have pointed out how ASCs have more osteogenic power in vivo [27, 29] . Interestingly, ASCs have been shown to up-regulate osteogenic genes in response to shear stress making them capable of responding to a mechanical load [18, 30] .
A practical example of surgical application could be represented by symptomatic clavicular delayed unions or clavicular non-unions. In the first scenario a simple percutaneous injection of purified, vital ASCs could be carried out under sonographic guide, directly into the fracture site. In the second instance the injection of vital ASCs could be done after open debridement of intervening tissue in the non-union and before definitive plate and screws fixation, in order to avoid the transplantation of autologous cancellous bone, a procedure that requires a second surgical intervention and has some surgical morbidity, as donor site pain or infection [31] .
Absolute contraindications to these or other procedures of bone reconstruction with ASCs are local or systemic infections, neoplastic bone loss, positive serology for HIV 1 or HIV-2, Hepatitis B (HBsAg), Hepatitis C (Anti-HCV-Ab) and immunosuppressive diseases.
As Filardo et al. reported in their systematic review [17] , ASCs have lower chondrogenic potentials than BM-MSCs. Chondrogenesis comparable to BM-MSCs can be induced from ASCs only using considerable doses of growth factors, thus making the application of ASCs for cartilage tissue-engineering poorly reproducible in vivo and expensive. The described technique is designed to inject cells for bone loss correction, but it is not suited for the treatment of surface loss, such as cartilaginous ones.
The procedure we describe is easy, fast, economic, and safe. Since it allows for the harvesting of a significant number of ASCs (ready for intraoperative use), we hope it might represent a useful advance in terms of regenerative procedures involving bone defects.
Anyhow it should be stressed that although it is not possible to assess the rate of survival of ASCs after injection in vivo in human subjects in the following days or weeks, a significative postoperative death rate of transplanted stem cells have to be expected. Manassero et al. [32] studied the survival rate and osteogenic ability of human MSCs in orthotopic and ectopic sites in mice. Less than 2% of the initial cell number was present 4 weeks postimplantation and less than 1% of the initial cell number by 8 weeks postimplantation. By 2 weeks postimplantation, the amount of newly formed bone was self-limited. Anyhow, by 10 weeks postimplantation, bone formation was significantly enhanced in the presence of MSCs in orthotopic site. These results indicated that MSCs promote bone formation despite early and massive cell death.
A major drawback of the technique, compared to lab-processed samples, is the lack of control of the quality of the sample before grafting. With our approach, the surgeon does not know how many cells will be reinjected on site.
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